MarketFriction

Vimta Labs Ltd

NSE VIMTALABS · BSE 524394 · Healthcare Research, Analytics & Technology
₹584.35 -2.66%
NSE close2026-10-01
52 week range376.05 - 774.70
Market cap₹2,642 Cr.
P/E32.7
Price band 20% Delivery 41.3%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales647373758590949810299109109
Expenses485047495557616468647072
Operating Profit172326263033333434343937
OPM %26%31%36%35%35%37%35%35%34%35%36%34%
Other Income0-1-1-1-15223034
Interest111001000000
Depreciation988881091010111313
Profit before tax81316172028252526232928
Tax %25%25%24%26%24%23%27%25%24%25%27%26%
Net Profit6912121522181920182121
EPS in Rs1.342.142.792.773.444.844.124.244.473.944.734.71
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales138154183213181209276315289344407419
Expenses119127138155151156196222195222266274
Operating Profit192745583053809494122142145
OPM %14%18%25%27%17%25%29%30%33%35%35%35%
Other Income11123103-4579
Interest125542232211
Depreciation101016202123233133354446
Profit before tax817263582855645590104107
Tax %23%36%36%28%17%25%26%26%25%25%25%
Net Profit6111625721414741677880
EPS in Rs1.452.403.725.731.574.819.2910.689.2615.1317.3517.85
Dividend Payout %34%0%27%17%0%21%11%9%11%7%12%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth11%14%9%14%
Compounded Profit Growth29%30%19%13%
Stock Price CAGR28%33%27%-15%
Return on Equity15%18%18%19%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital444444444449
Reserves118122132148167169190229276310374448
Borrowings426444026323019151993
Other Liabilities2123424040394954656179102
Total Liabilities146176222232237245273306360394467562
Fixed Assets888888140135131128162168166230305
CWIP065304217012593818
Investments000006666002
Other Assets5882809299105122138174170198237
Total Assets146176222232237245273306360394467562
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity15-1243339243759876194147
Cash from Investing Activity-8-16-39-24-16-20-32-38-57-76-76-130
Cash from Financing Activity-91913-8-23-1-5-16-11-2-16-10
Net Cash Flow-12-21131519-1727
Free Cash Flow8-17-169231052037-141747
CFO/OP96%4%107%86%85%101%84%94%106%81%95%121%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days821001011111001171281029311011395
Inventory Days158213183209199191140154195260210203
Days Payable6677184148115114139108124878879
Cash Conversion Cycle174236100172184194128147164283235219
Working Capital Days1099922627864898778989683
ROCE %6%7%11%17%21%6%14%24%24%20%25%25%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters37.00%36.98%36.92%36.89%36.89%36.76%36.70%36.67%35.99%35.89%35.85%35.66%
FIIs2.74%2.88%5.13%5.16%3.31%3.81%3.66%3.49%4.33%4.59%4.89%4.41%
DIIs1.50%1.49%1.50%1.49%0.00%1.15%1.43%1.42%0.87%0.11%0.13%0.37%
Public58.75%58.65%56.45%56.45%59.80%58.28%58.20%58.42%58.80%59.40%59.12%59.55%
No. of Shareholders18,42919,95718,55019,05420,11421,15626,18330,82955,93354,46751,62350,190

Fundamentals

Market Cap₹ 2,642 Cr.
Current Price₹ 591
Stock P/E32.7
Book Value₹ 102
ROCE25.2 %
ROE18.9 %
Dividend Yield0.34 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)14%
Compounded Profit Growth (TTM)13%
Standalone figures.
Valuation
Market capRs 2,610 Cr
Enterprise valueRs 2,549 Cr
P/E (TTM)32.77x
Price to book5.71x
Price to sales6.23x
EV / EBITDA16.49x
EV / EBIT23.57x
EV / sales6.09x
Price to cash flow17.74x
Earnings yield3.05%
Dividend yield0.34%
P/E, 3-year average16.84x
P/B, 3-year average2.75x
P/E, 5-year average13.27x
P/B, 5-year average2.19x
Profitability
Operating margin (excl. other income)34.79%
Operating margin (incl. other income)36.56%
EBITDA margin36.91%
Pre-tax margin25.56%
Net profit margin19.02%
Net margin, latest quarter19.29%
ROE18.55%
ROCE24.81%
ROA15.07%
ROE, 3-year average17.26%
ROCE, 3-year average22.75%
ROA, 3-year average13.86%
ROE, 5-year average17.87%
ROCE, 5-year average23.27%
ROA, 5-year average13.99%
ROIC (approx.)20.40%
Tax rate25.43%
Other income / net worth1.58%
Growth
Sales growth (latest year)18.41%
Profit growth (latest year)15.10%
Sales CAGR, 3 years8.93%
Sales CAGR, 5 years14.27%
Profit CAGR, 3 years17.90%
Profit CAGR, 5 years29.53%
Sales growth QoQ-0.16%
Profit growth QoQ-0.33%
Sales growth YoY (latest quarter)11.80%
Profit growth YoY (latest quarter)11.38%
Per share
EPS (TTM)Rs 17.83
EPS (latest year)Rs 17.35
EPS (latest quarter)Rs 4.71
EPS, 3-year averageRs 22.05
EPS, 5-year averageRs 21.22
Book value per shareRs 102.28
Sales per shareRs 93.76
Cash flow per shareRs 32.94
Free cash flow per shareRs 10.52
Dividend per share (latest year)Rs 2.00
Dividend per share, 3-year averageRs 2.00
Dividend per share, 5-year averageRs 2.00
Dividends
Dividend payout11.52%
Dividend payout, 3-year average9.64%
Dividend payout, 5-year average9.81%
Efficiency
Asset turnover0.72x
Fixed asset turnover1.33x
Inventory turnover3.43x
Inventory days106 days
Debtor days95 days
Debtors turnover3.85x
Creditor days79 days
Cash conversion cycle219 days
Working capital days83 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 65 Cr
Net debtRs -62 Cr
Debt to equity0.01x
Net debt / EBITDA-0.40x
Interest coverage99.19x
Current ratio (filing 2026-03-31)3.43x
Quick ratio (filing 2026-03-31)2.97x
Trade payables (filing 2026-03-31)Rs 12 Cr
Owners' fund to total sources81.26%
Debt to assets0.59%
Cash flow
Cash from Operating Activity (latest year)Rs 147 Cr
Cash from Investing Activity (latest year)Rs -130 Cr
Cash from Financing Activity (latest year)Rs -10 Cr
Net Cash Flow (latest year)Rs 7 Cr
Free cash flow (latest year)Rs 47 Cr
FCFE (approx.: FCF + change in debt)Rs 42 Cr
Cash from ops / profit, 5 years1.64x
Sales to cash flow2.77x
Statement figures
Net sales (TTM)Rs 419 Cr
Net sales (latest year)Rs 407 Cr
Sales (latest quarter)Rs 109 Cr
Operating profit excl. other income (latest year)Rs 142 Cr
Operating profit (latest quarter)Rs 37 Cr
Other income (TTM)Rs 9 Cr
EBITDA (TTM)Rs 155 Cr
PBDT (TTM)Rs 153 Cr
Profit before tax (TTM)Rs 107 Cr
Tax (latest year)Rs 26 Cr
Net profit (TTM)Rs 80 Cr
Net profit (latest year)Rs 78 Cr
Net profit (latest quarter)Rs 21 Cr
Depreciation (TTM)Rs 46 Cr
Depreciation (latest quarter)Rs 13 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 103 Cr
Total expenditure (latest year)Rs 266 Cr
Total income (latest year)Rs 414 Cr
Share capitalRs 9 Cr
ReservesRs 448 Cr
Shareholders' fundsRs 457 Cr
Total assetsRs 562 Cr
Net blockRs 305 Cr
Capital work in progressRs 18 Cr
InvestmentsRs 2 Cr
ReceivablesRs 106 Cr
InventoryRs 30 Cr
Other liabilitiesRs 102 Cr
Shares outstanding (crore)4.47
Ownership
Promoter holding35.66% (-1.01 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 32.8 is at the 57th percentile of its own 9.4-year range (median 30.0, low 5.3, high 82.7).
P/B 5.71 is at the 84th percentile (median 3.63).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodVIMTALABSNifty 50Difference
1 week-2.2%-2.8% +0.6 pts
1 month-11.7%-6.8% -4.9 pts
3 months-0.2%-7.6% +7.4 pts
6 months+53.5%+0.4% +53.1 pts
1 year-22.2%-9.9% -12.2 pts
2 years+105.1%-13.6% +118.6 pts
3 years+102.0%+14.2% +87.8 pts
5 years+319.9%+27.9% +292.1 pts
2 mutual fund schemes hold about ₹7 Cr. Over three months 1 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
WOC Pharma and Healthcare Fund0.73%7 +5%
Bandhan BSE Healthcare Index Fund0.06%0 +5%

Red flags

F-score 5 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹109 Cr +11.2% vs Jun 2025. Net profit ₹21 Cr +10.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Syngene International Ltd14,82350.09.99 %
Indegene Ltd14,58035.018.8 %
Suven Life Sciences Ltd9,176-79.5 %
Fabtech Technologies Ltd66113.613.6 %
Bilcare Ltd22911.57.06 %
Take Ltd20835.218.5 %
Novelix Pharmaceuticals Ltd19955.110.9 %
Jeevan Scientific Technology Ltd16346.75.01 %
Adeshwar Meditex Ltd2419.45.21 %
Vanta Bioscience Ltd151331.19 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-06-18Dividend - Rs 2 Per Share
2025-06-13Bonus 1:10.5000
2025-05-30Dividend - Rs 2 Per Share
2024-07-11Annual General Meeting/Dividend - Rs 2 Per Share
2023-06-21Annual General Meeting/Dividend - Rs 2 Per Share
2022-06-16Annual General Meeting/Dividend - Rs 2 Per Share
2021-06-25 Annual General Meeting/Dividend - Rs 2 Per Share
2020-09-01 Annual General Meeting
2019-07-18 Annual General Meeting/Dividend - Rs 2 Per Share
2018-08-14 Annual General Meeting/Dividend- Rs 2 Per Share
2017-09-19 Annual General Meeting
2016-08-25 Annual General Meeting/Dividend Re 1/- Per Share
2015-08-06 Annual General Meeting/Dividend - Re 1/- Per Share
2014-06-27Annual General Meeting/Dividend Rs 2/- Per Share
2013-05-23Annual General Meeting / Final Dividend Re.0.60/- Per Equity Share
2012-09-06Annual General Meeting
2011-09-15Annual General Meeting And Dividend Re.0.40 Per Share
2010-09-23Annual General Meeting And Dividend Re.0.80 Per Share
2009-09-10Ann Clsng/Dv-Re.0.80 P Sh
2008-08-28Agm/Dividend - 40%
2007-08-02Agm/Dividend-40%
2006-06-01Agm/Dividend-40%
DateTypeWhat it says
2026-09-16AllotmentAllotment of 12955 securities pursuant to ESOP/ESPS at its meeting held on September 16, 2026
2026-09-08Concall / analyst meetSchedule of meet
2026-09-02Credit RatingCredit Rating
2026-08-31Volume querySignificant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant informati...
2026-08-31Volume querySignificant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant informati...
2026-08-29Concall / analyst meetSchedule of meet
2026-08-29Concall / analyst meetSchedule of meet
2026-08-21UpdatesIntimation on Cyber Security Incident.
2026-07-28Concall / analyst meetSchedule of meet
2026-07-28Concall / analyst meetSchedule of meet
2026-07-24Concall / analyst meetTranscript
2026-07-20Concall / analyst meetLink of Recording
2026-07-20Press ReleaseA press release dated July 20, 2026, titled "Vimta Labs Limited Q1 FY27 Results".
2026-07-20Investor PresentationInvestor Presentation
2026-07-20Board meeting outcomeVimta Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-15Concall / analyst meetSchedule of meet
2026-07-04UpdatesUpdate on Payment of Dividend.
2026-07-01AllotmentAllotment of 17549 securities pursuant to ESOP/ESPS at its meeting held on July 01, 2026
2026-06-29Disclosure under SEBI TakeovVimta Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantia...
2026-06-25Shareholder meetingShareholders meeting
2026-06-25Shareholder meetingProceedings of Annual General Meeting held on Jun 25, 2026
2026-06-02Concall / analyst meetSchedule of meet
2026-06-02Disclosure under SEBI TakeovVimta Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantia...
2026-06-01Shareholder meetingNotice of Annual General Meeting to be held on Jun 25, 2026
2026-05-29Concall / analyst meetSchedule of meet
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Vimta Labs Ltd?

Vimta Labs Ltd (VIMTALABS) has a market capitalisation of Rs 2,642 Cr. at the 2026-10-01 close.

What is the P/E ratio of Vimta Labs Ltd?

Vimta Labs Ltd trades at a P/E of 32.7 on trailing twelve-month profit, at the 2026-10-01 close.

What were Vimta Labs Ltd's latest quarterly results?

In the Jun 2026 quarter, Vimta Labs Ltd sales was Rs 109 Cr (+11.2% vs Jun 2025) and net profit was Rs 21 Cr.

What is the 52-week high and low of Vimta Labs Ltd?

The 52-week high is Rs 774.70 and the 52-week low is Rs 376.05.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03